KR20090120011A - 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법 - Google Patents

고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법 Download PDF

Info

Publication number
KR20090120011A
KR20090120011A KR1020097022363A KR20097022363A KR20090120011A KR 20090120011 A KR20090120011 A KR 20090120011A KR 1020097022363 A KR1020097022363 A KR 1020097022363A KR 20097022363 A KR20097022363 A KR 20097022363A KR 20090120011 A KR20090120011 A KR 20090120011A
Authority
KR
South Korea
Prior art keywords
ibandronate sodium
solution
sodium
hours
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097022363A
Other languages
English (en)
Korean (ko)
Inventor
레비털 리프쉬츠-리론
토마스 베이어
주디스 아론힘
마이클 핀차소브
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090120011(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20090120011A publication Critical patent/KR20090120011A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Battery Electrode And Active Subsutance (AREA)
KR1020097022363A 2004-08-23 2005-08-23 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법 Ceased KR20090120011A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US60/604,026 2004-08-23
US69086705P 2005-06-16 2005-06-16
US60/690,867 2005-06-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077005922A Division KR20070043043A (ko) 2004-08-23 2005-08-23 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법

Publications (1)

Publication Number Publication Date
KR20090120011A true KR20090120011A (ko) 2009-11-23

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097022363A Ceased KR20090120011A (ko) 2004-08-23 2005-08-23 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
KR1020077005922A Ceased KR20070043043A (ko) 2004-08-23 2005-08-23 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077005922A Ceased KR20070043043A (ko) 2004-08-23 2005-08-23 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법

Country Status (12)

Country Link
US (1) US7563918B2 (enExample)
EP (2) EP1930011B1 (enExample)
JP (1) JP4559431B2 (enExample)
KR (2) KR20090120011A (enExample)
CN (1) CN101022812A (enExample)
AT (2) ATE520406T1 (enExample)
CA (1) CA2576659A1 (enExample)
DE (2) DE602005025977D1 (enExample)
ES (1) ES2358269T3 (enExample)
IL (1) IL181298A (enExample)
PT (2) PT1930011E (enExample)
WO (1) WO2006024024A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
AU2006210008B2 (en) * 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (en) * 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
EP2046342A4 (en) * 2006-07-28 2011-05-04 Reddys Lab Ltd Dr CRYSTALLINE FORM WITH IBANDRONIC ACID AND PROCESS FOR PREPARING THE SAME
JP2009516004A (ja) * 2006-11-16 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド イバンドロン酸ナトリウムの結晶形態
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
MX2009010850A (es) 2007-04-11 2009-11-02 Hoffmann La Roche Sintesis de ibandronato en multiples etapas.
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US9192316B2 (en) 2009-05-15 2015-11-24 Nox Medical Systems and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
CA2833111C (en) 2010-06-25 2018-08-21 Kormakur Hlini Hermannsson Biometric belt connector
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
EP3065638B1 (en) 2013-11-06 2024-01-10 Nox Medical ehf. Method, apparatus, and system for measuring respiratory effort
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3500155B1 (en) 2016-08-19 2024-10-02 Nox Medical Method, system, and computer program for measuring respiratory effort of a subject
EP3629893A1 (en) 2017-06-02 2020-04-08 Nox Medical ehf. Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
EP3678543A1 (en) 2017-09-08 2020-07-15 Nox Medical System and method for non-invasively determining an internal component of respiratory effort

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ES2254410T3 (es) * 2000-05-05 2006-06-16 F. Hoffmann-La Roche Ag Composicion farmaceutica como gel para administracion subcutanea que comprende acidos bisfosfonicos o sus sales.
ES2247123T7 (es) * 2000-06-20 2013-03-01 Novartis Ag Método para administrar bisfosfonatos
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
MXPA02001219A (es) * 2001-02-01 2005-06-06 Riderway Corp Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
PT1880744E (pt) * 2002-05-10 2015-02-13 Hoffmann La Roche Ácidos bisfosfónicos para o tratamento e a prevenção da osteoporose
US20050287135A1 (en) * 2002-05-17 2005-12-29 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
EP2206717B1 (en) * 2003-12-23 2013-03-27 Alchymars S.p.A. A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
AU2006210008B2 (en) 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (en) 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
CA2576659A1 (en) 2006-03-02
US20070179119A1 (en) 2007-08-02
DE602005025977D1 (de) 2011-03-03
IL181298A0 (en) 2007-07-04
EP1930011A2 (en) 2008-06-11
PT1713489E (pt) 2011-03-03
EP1713489B1 (en) 2011-01-19
CN101022812A (zh) 2007-08-22
JP2007512237A (ja) 2007-05-17
EP1713489A2 (en) 2006-10-25
WO2006024024A3 (en) 2006-06-29
WO2006024024A2 (en) 2006-03-02
EP1930011B1 (en) 2011-08-17
KR20070043043A (ko) 2007-04-24
IL181298A (en) 2011-04-28
US7563918B2 (en) 2009-07-21
ATE495747T1 (de) 2011-02-15
JP4559431B2 (ja) 2010-10-06
ATE520406T1 (de) 2011-09-15
PT1930011E (pt) 2011-09-16
EP1930011A3 (en) 2008-06-18
ES2358269T3 (es) 2011-05-09
DE202005021414U1 (de) 2008-03-20

Similar Documents

Publication Publication Date Title
KR20090120011A (ko) 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
EP3820851A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
KR20080055990A (ko) 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
WO2021021775A1 (en) Solid state forms of risdiplam and process for preparation thereof
EP3830184A1 (en) Solid state forms of sugammadex sodium
KR20060015750A (ko) 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
US20040235904A1 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
WO2009042179A1 (en) Crystalline forms of ibandronic acid and processeses for the preparation thereof
WO2021216628A1 (en) Solid state forms of trifarotene and process for preparation thereof
WO2021119223A1 (en) Solid state form of lemborexant
EP2009016A2 (en) Process for preparing crystalline form of ibandronate sodium
MX2007002286A (en) Solid and crystalline ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) Amorphous and crystalline forms of ibandronate disodium
US20220220149A1 (en) Solid state forms of sage-217 and processes for preparation thereof
WO2025017530A1 (en) Solid state forms of buntanetap and process for preparation thereof
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법
WO2024176164A1 (en) Solid state form of pirtobrutinib
WO2020086789A1 (en) New crystalline polymorphs of rigosertib sodium
US20090042839A1 (en) Crystalline forms of ibandronate sodium

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000